News
Bird Flu Threat Still Looms, But HHS Just Canceled a Moderna Contract That Could Prepare for It
Messenger RNA technology offers a faster way to develop vaccines to address or prepare for pandemics, and Moderna’s vaccine candidate for avian influenza is on track for Phase 3 testing. But the Department of Health and Human Services has canceled a $590 million contract to support Moderna's pivotal trial.
The Health and Human Services Department, led by vaccine skeptic Robert F. Kennedy Jr., has canceled $766 million in payments ...
Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.
Live Science on MSN12d
2-in-1 COVID-flu vaccine looks promising, but approval could be delayedLate-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect ...
The amount of the funding cut is significant for a company of Moderna's size. It reported a total of $1 billion in sales for the fourth quarter of 2024, and expects 2025 revenue to be between $1.5 to ...
U.S. health officials are terminating a $590 million contract with Moderna Inc. to develop vaccines for bird flu, a major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback